Robert Wasserman
Stock Analyst at Benchmark
(3.32)
# 1,006
Out of 5,147 analysts
125
Total ratings
48.62%
Success rate
2.99%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Upgrades: Buy | $95 | $86.68 | +9.60% | 13 | Feb 20, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $90 | $69.53 | +29.44% | 11 | Feb 19, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $175 → $220 | $198.31 | +10.94% | 12 | Nov 7, 2025 | |
| PRLB Proto Labs | Maintains: Buy | $45 → $55 | $62.08 | -11.40% | 7 | Nov 3, 2025 | |
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $100 → $38 | $7.66 | +389.56% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $59.00 | +27.12% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $8.70 | +72.41% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.72 | +248.84% | 9 | May 12, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $25.53 | +37.09% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $3.61 | - | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $24.20 | +23.97% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $8 | $0.36 | +2,122.22% | 6 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $3.91 | +27.88% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $8.15 | +47.24% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.01 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $128.73 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $3.44 | +16.25% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $100 | $2.17 | +4,508.29% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $3.42 | +2,092.98% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $210.64 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $521.11 | +11.30% | 1 | Jul 16, 2021 |
Integer Holdings
Feb 20, 2026
Upgrades: Buy
Price Target: $95
Current: $86.68
Upside: +9.60%
Halozyme Therapeutics
Feb 19, 2026
Maintains: Buy
Price Target: $75 → $90
Current: $69.53
Upside: +29.44%
Ligand Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $175 → $220
Current: $198.31
Upside: +10.94%
Proto Labs
Nov 3, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $62.08
Upside: -11.40%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $100 → $38
Current: $7.66
Upside: +389.56%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $59.00
Upside: +27.12%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $8.70
Upside: +72.41%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.72
Upside: +248.84%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $25.53
Upside: +37.09%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $3.61
Upside: -
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $24.20
Upside: +23.97%
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $0.36
Upside: +2,122.22%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $3.91
Upside: +27.88%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $8.15
Upside: +47.24%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $1.01
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $128.73
Upside: -
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $3.44
Upside: +16.25%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $100
Current: $2.17
Upside: +4,508.29%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $3.42
Upside: +2,092.98%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $210.64
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $521.11
Upside: +11.30%